Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clar Vision is an oral dietary supplement developed by Iromed Group S.r.l., an Italian ophthalmic company, specifically formulated to support the health of the vitreous body. It is primarily indicated for individuals experiencing vitreous degeneration, commonly manifested as myodesopsia or "eye floaters." The formulation is a combination of proteolytic enzymes, including bromelain and papain, which are intended to aid in the breakdown of collagen aggregates within the vitreous humor. Additionally, it contains a blend of antioxidants such as Vitamin C and Vitamin E, minerals like Zinc, Magnesium, and Potassium, and the amino acid Taurine. These components work synergistically to protect ocular tissues from oxidative stress, maintain electrolyte balance, and support the structural integrity of the connective tissue within the eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clar Vision.